| Impact Factor 15.358* | In this issue
  Research Highlights
News and Views
Reviews
Consensus Statement
Also this month
 Featured article:
MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-establishing disease prognosis and monitoring patients
Mike P. Wattjes, Àlex Rovira, David Miller, Tarek A. Yousry, Maria P. Sormani, Nicola de Stefano, Mar Tintoré, Cristina Auger, Carmen Tur, Massimo Filippi, Maria A. Rocca, Franz Fazekas, Ludwig Kappos, Chris Polman, Frederik Barkhof & Xavier Montalban; on behalf of the MAGNIMS study group |
|
| |
 | | | | | | | | NEWS AND VIEWS | Top | Dementia: Cerebrospinal fluid biomarkers in dementias
Peter Paul De Deyn
Published online: 15 September 2015
p549 | doi:10.1038/nrneurol.2015.175
A new study describes a biomarker profile based on cerebrospinal fluid (CSF) tau and amyloid-β1-42 in a uniquely large population with a variety of dementia diagnoses. This study confirms the differential diagnostic value of CSF biomarkers and further highlights the important neuropathological overlap between dementia aetiologies.
Full Text | PDF
| Epilepsy: Intriguing new data on epilepsy and risks at delivery
Lina Nashef & Torbjörn Tomson
Published online: 15 September 2015
p550 | doi:10.1038/nrneurol.2015.176
A large study from the USA suggests that epilepsy in pregnant women elevates the risk of adverse events both to the mother and the fetus, including an 11-fold increase in the risk of death of the mother at delivery. Although the data are intriguing, the study has caveats that call for cautious interpretation.
Full Text | PDF
| Stroke: Stroke prevention—time to say goodbye to the ABCD2 score?
Hans-Christoph Diener & Benedikt Frank
Published online: 01 September 2015
p552 | doi:10.1038/nrneurol.2015.156
The ABCD2 score was developed to triage patients with transient ischaemic attack according to the risk of experiencing a stroke in the next few hours or days. However, a new systematic review and meta-analysis on the ABCD2 score gives us considerable cause to rethink its value for clinical situations.
Full Text | PDF
| Parkinson disease: Laying the foundations for disease-modifying therapies in PD
Patrik Brundin & Richard Wyse
Published online: 25 August 2015
p553 | doi:10.1038/nrneurol.2015.150
The results of a futility trial, which used the PPAR-γ receptor agonist pioglitazone in an attempt to modify disease progression in Parkinson disease, do not support initiation of further trials. However, although this trial was well designed and conducted, we question whether it is time to fully shut the door on pioglitazone.
Full Text | PDF
| | | | | REVIEWS | Top | Circulating biomarkers for gliomas
Manfred Westphal & Katrin Lamszus
Published online: 15 September 2015
p556 | doi:10.1038/nrneurol.2015.171
Blood-derived biomarkers for gliomas would facilitate diagnostic and prognostic evaluation and assessment of treatment response. Extracellular vesicles, in particular, could be valuable, because they contain a variety of microRNAs, tumour DNA and metabolic markers that reflect the heterogeneous composition of the tumour. Here, Westphal and Lamszus provide an overview of the state of the art, prospects and challenges in development of circulating biomarkers for gliomas.
Abstract | Full Text | PDF
| Monoamine neurotransmitter disorders—clinical advances and future perspectives
Joanne Ng, Apostolos Papandreou, Simon J. Heales & Manju A. Kurian
Published online: 22 September 2015
p567 | doi:10.1038/nrneurol.2015.172
Monoamine neurotransmitters are involved in many neurological functions, and defects in their synthesis, metabolism and transport leads to a variety of disorders with subtly different clinical manifestations that make them difficult to diagnose. The authors of this Review outline the clinical features, diagnosis and management of monoamine neurotransmitter disorders, and consider recent and future advances in knowledge and therapeutic options.
Abstract | Full Text | PDF
| Body fluid biomarkers for multiple sclerosis—the long road to clinical application
Charlotte E. Teunissen, Arjan Malekzadeh, Cyra Leurs, Claire Bridel & Joep Killestein
Published online: 22 September 2015
p585 | doi:10.1038/nrneurol.2015.173
The diagnosis and monitoring of multiple sclerosis (MS) still relies largely on clinical manifestations and imaging. Blood-based or cerebrospinal fluid biomarkers to facilitate prognostic evaluation, staging and subtyping of MS, as well as to predict treatment response and adverse effects, are sorely needed. This comprehensive Review by Charlotte Teunissen and colleagues provides an update on advances in biomarker development and validation in MS, focusing on the clinical applications of MS biomarkers.
Abstract | Full Text | PDF | Supplementary information
| | | | | CONSENSUS STATEMENT | Top | Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients
Mike P. Wattjes, Àlex Rovira, David Miller, Tarek A. Yousry, Maria P. Sormani, Nicola de Stefano, Mar Tintoré, Cristina Auger, Carmen Tur, Massimo Filippi, Maria A. Rocca, Franz Fazekas, Ludwig Kappos, Chris Polman, Frederik Barkhof, Xavier Montalban & on behalf of the MAGNIMS study group
Published online: 15 September 2015
p597 | doi:10.1038/nrneurol.2015.157
In the second part of the MAGNIMS network's evidence-based guidelines, Wattjes and colleagues discuss the use of MRI in prognostication and follow-up in patients with multiple sclerosis. The group recommend several techniques that are useful for monitoring disease activity and treatment efficacy, and identify those techniques that require further study.
Abstract | Full Text | PDF
| | | | | | | Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com | | | | | |
|
*2014 Journal Citation Reports (Thomson Reuters, 2015). Nature Reviews Neurology was previously published as Nature Clinical Practice Neurology.
|
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. |
 |
|
No comments:
Post a Comment
Keep a civil tongue.